NEOPLASIA : Impact Factor & More
eISSN: 1476-5586pISSN: 1476-5586
Share this on:
Key Metrics
Impact Factor 
< 5
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on NEOPLASIA
NEOPLASIA Journal Specifications
Indexed in the following public directories
Web of Science 
SJR
| Overview | |
| Publisher | ELSEVIER SCIENCE INC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1999 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in NEOPLASIA ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in NEOPLASIA
Fusion gene heterogeneity and kinase enrichment in high-grade serous carcinomas.
- 1 Sep 2026
- Neoplasia (New York, N.Y.)
The benefit of deep genomic testing for asymptomatic high-risk individuals undergoing surveillance for pancreatic adenocarcinoma: European registry for hereditary pancreatic diseases (EUROPAC-PLUS).
- 1 Sep 2026
- Neoplasia (New York, N.Y.)
DRIVE: a comprehensive resource deciphering drug-induced transcriptomic and splicing response in cancer cell.
- 1 Sep 2026
- Neoplasia (New York, N.Y.)
Corrigendum to "Activation of PERK/eIF2α/ATF4 signaling inhibits ERα expression in breast cancer" [Neoplasia 65 (2025) 101165
- 1 Sep 2026
- Neoplasia (New York, N.Y.)
The importance of HPV testing in oropharyngeal cancer in two US populations.
- 1 Sep 2026
- Neoplasia (New York, N.Y.)
Hypoxia-activated PROTAC for dual inhibition of FAK and EGFR enables synergistic mechano-chemical cancer therapy.
- 1 Sep 2026
- Neoplasia (New York, N.Y.)
Fusion gene heterogeneity and kinase enrichment in high-grade serous carcinomas.
- 1 Sep 2026
- Neoplasia (New York, N.Y.)
The benefit of deep genomic testing for asymptomatic high-risk individuals undergoing surveillance for pancreatic adenocarcinoma: European registry for hereditary pancreatic diseases (EUROPAC-PLUS).
- 1 Sep 2026
- Neoplasia (New York, N.Y.)
DRIVE: a comprehensive resource deciphering drug-induced transcriptomic and splicing response in cancer cell.
- 1 Sep 2026
- Neoplasia (New York, N.Y.)
Corrigendum to "Activation of PERK/eIF2α/ATF4 signaling inhibits ERα expression in breast cancer" [Neoplasia 65 (2025) 101165
- 1 Sep 2026
- Neoplasia (New York, N.Y.)
The importance of HPV testing in oropharyngeal cancer in two US populations.
- 1 Sep 2026
- Neoplasia (New York, N.Y.)
Hypoxia-activated PROTAC for dual inhibition of FAK and EGFR enables synergistic mechano-chemical cancer therapy.
- 1 Sep 2026
- Neoplasia (New York, N.Y.)
FAQs on NEOPLASIA
How long has NEOPLASIA been actively publishing? 
What is the publishing frequency of NEOPLASIA?
How many articles did NEOPLASIA publish last year?
What is the eISSN & pISSN for NEOPLASIA?
Who is the publisher of NEOPLASIA?
